# US 2021/0330660 A1 · Formulations for cgrp receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330660 A1
- Document ID: US20210330660A1
- Status: Published application
- Kind: A1
- Application number: 17/114,169
- Filed: 2020-12-07
- Published: 2021-10-28
- Earliest claimed: 2013-09-16
- Inventors: Majid Mahjour; Leonardo R. Allain; Sutthilug Sotthivirat; Russell G. Maus; Rebecca Nofsinger; Lisa Lupton; Wei Xu; Francis Flanagan
- Web page: https://patentgrep.com/patent/US20210330660A1

## CPC

- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 25/06: Antimigraine agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists. The CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache.

## Claims

### Claim 1

A liquid pharmaceutical composition comprising (S)-N-((3S, 5S, 6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidine-3-yl)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxamide trihydrate present in an amount of 0.25% to 2% by weight of the composition, and a pharmaceutically acceptable carrier comprising VitE-TPGS, polyvinylpyrrolidone, PEG 400, and propylene glycol.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the carrier further comprises water.

### Claim at position 5

5-9. (canceled)

### Claim 10 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the VitE-TPGS is present in an amount of 0.1% to 15.0% by weight of the composition.

### Claim 11 (depends on 10)

The liquid pharmaceutical composition according to claim 10, wherein the VitE-TPGS is present in an amount of 2.5% to 10% by weight of the composition

### Claim at position 8

12-14. (canceled)

### Claim 15 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the volume of carrier is less than 5 mL.

### Claim 16 (depends on 1)

The liquid pharmaceutical composition according to claim 1, further comprising one or more pharmaceutically acceptable excipients selected from the group consisting of anti-nucleating polymers, antioxidants, chelating agents, souring agents, sodium chloride, colors, sweeteners and flavors.

### Claim 17 (depends on 1)

The liquid pharmaceutical composition according to claim 1 further comprising, Water, Sucralose, Menthol, and a mint or peppermint flavor.

### Claim 18 (depends on 17)

The liquid pharmaceutical composition according to claim 17, which further comprises a souring agent.

### Claim 19 (depends on 1)

A method of treating migraine headache by administering a liquid pharmaceutical composition according to claim 1.

### Claim 20 (depends on 17)

A method of treating migraine headache by administering a liquid pharmaceutical composition according to claim 17.

### Claim 21 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the VitE-TPGS is present in an amount of about 10.00% by weight of the composition.

### Claim 22 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the polyvinylpyrrolidone is present in an amount of about 1.00% by weight of the composition.

### Claim 23 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the PEG 400 is present in an amount of about 33.61% by weight of the composition.

### Claim 24 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the propylene glycol is present in an amount of about 33.61% by weight of the composition.

### Claim 25 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the CGRP receptor antagonist is present in an amount of about 1.38% by weight of the composition.
